A Certificate of Analysis is supposed to be the final word on what is actually inside a peptide vial or capsule. In practice, the document circulating on many research supplier websites is little more than a formatted PDF with numbers that have never been independently verified. Knowing how to read a legitimate peptide COA — and how to spot a fraudulent one — is one of the most practical skills a research buyer can develop. This guide covers every element that belongs on a credible COA, the three non-negotiable tests, and the specific red flags that should end a supplier relationship before it starts.
A Certificate of Analysis (COA) is a formal document issued by a testing laboratory that records the results of analytical assays performed on a specific batch of compound. In the context of research-grade peptides, a COA serves a straightforward purpose: it provides objective, third-party evidence that the material in question is what the label claims, at the stated purity level, and free from specific classes of contamination that would compromise experimental integrity.
The operative phrase is “third-party.” A COA generated by the same organization that synthesized the peptide is not independent verification — it is self-reporting. Independent verification requires a laboratory with no commercial interest in the outcome, accredited instrumentation, and documented chain-of-custody between the batch and the analytical result. When those elements are present, a COA becomes a meaningful data point. When they are absent, it is marketing collateral dressed as science.
For researchers, the COA also functions as a reproducibility tool. If two different laboratories use the same peptide lot to run parallel experiments, the COA gives them a shared reference point for the compound’s composition. Without batch-level COA data, comparing results across experiments becomes significantly more difficult, because you cannot rule out compound variability as a confounding variable.
You can review Biohacker’s full library of published COAs at our COA page, where every batch is documented and searchable by lot number.
Not all analytical methods are equivalent, and no single test tells the complete story. A rigorous peptide COA requires a minimum of three distinct assay types, each of which answers a different question about the material’s identity, quality, and safety profile.
High-Performance Liquid Chromatography (HPLC) is the standard method for quantifying the purity of a synthesized peptide. The technique works by dissolving the sample in a mobile phase solvent and pushing it through a column packed with a stationary phase material. Different molecular species travel through the column at different rates based on their chemical interactions with the stationary phase. A detector — typically UV absorbance at 214–220 nm, which captures the peptide bond — records a chromatogram: a graph of detector signal versus retention time.
The target compound elutes at a characteristic retention time and produces a peak. All other peaks in the chromatogram represent impurities — synthesis by-products, deletion sequences, oxidized residues, or residual protecting groups from the Fmoc solid-phase synthesis process. Purity is calculated as the area of the target peak divided by the total area of all peaks, expressed as a percentage.
A result of ≥99% HPLC purity means that 99% or more of the UV-absorbing material in the sample is the target compound. The remaining ≤1% represents the aggregate contribution of all detected impurities. This threshold matters because even small amounts of structurally similar impurities can introduce variability into research outcomes. A peptide analogue or truncated sequence that differs by a single amino acid may have substantially different receptor binding characteristics, metabolic stability, or biological activity — none of which would be apparent without high-resolution purity data.
Biohacker’s catalogue averages 99.67% HPLC purity across all batches, a figure that reflects consistent upstream synthesis quality combined with rigorous lot-level testing before any material is made available for research purposes.
What the COA should show: the chromatogram image itself (not just a number), the area integration table listing each peak and its percentage contribution, the column specification, the mobile phase gradient, and the wavelength used for detection. A purity figure without the supporting chromatogram data is unverifiable.
Electrospray Ionization Mass Spectrometry (ESI-MS) is the identity confirmation test that HPLC alone cannot provide. HPLC tells you how pure the sample is; ESI-MS tells you whether the major component is actually the peptide you ordered.
In ESI-MS, the sample is ionized by passing it through a charged electrospray needle, producing multiply-charged ions that are separated by a mass analyzer according to their mass-to-charge ratio (m/z). The resulting mass spectrum shows the molecular mass of the compound with high precision — typically to within 1 Dalton or better.
The test works by comparing the observed molecular weight against the theoretical molecular weight calculated from the peptide’s amino acid sequence. If a peptide has been correctly synthesized — the right sequence, the right molecular formula — the mass spectrum will show a series of multiply-charged ions whose m/z values, when back-calculated, yield a mass consistent with the theoretical value. Any significant deviation indicates a problem: a miscoupled residue, a racemized amino acid, an incomplete deprotection step, or a structurally distinct impurity masquerading as a high-purity sample on the HPLC trace.
This is why HPLC alone is insufficient. It is technically possible to have a sample that shows 99% purity by HPLC but contains the wrong peptide — for example, if a synthesis error produced a compound with similar hydrophobicity to the target, causing it to co-elute at nearly the same retention time. ESI-MS would immediately flag this discrepancy. A COA that lacks mass spectrometry data is missing a fundamental identity check.
The COA should display the observed monoisotopic or average molecular weight, the theoretical molecular weight, and the mass spectrum showing the characteristic charge-state envelope. The deviation between observed and theoretical should be clearly stated and within instrument tolerance.
Endotoxins are lipopolysaccharide (LPS) fragments shed from the outer membrane of gram-negative bacteria. They are extraordinarily potent immunological stimulants: concentrations as low as 0.1 endotoxin units per millilitre (EU/mL) can trigger measurable inflammatory responses in sensitive biological systems. In cell culture, even sub-threshold endotoxin levels can confound assays involving cytokine signalling, NF-κB pathway activation, macrophage function, and numerous other inflammation-adjacent readouts.
The United States Pharmacopeia chapter <85> (USP <85>) defines the standard for endotoxin testing using the Limulus Amebocyte Lysate (LAL) assay or recombinant Factor C (rFC) methods. These tests detect endotoxin at the EU/mL level and are the reference standard for parenteral pharmaceutical products. Research-grade peptides that will be used in cell-based assays or in vivo models should meet a defined endotoxin limit — typically <1.0 EU/mg or lower depending on the application — documented against USP <85> methodology.
A supplier that does not include endotoxin data on the COA is leaving a significant research variable uncontrolled. If a researcher observes an unexpected inflammatory or cell-death signal in a peptide-treated group, and no endotoxin data exists for that lot, ruling out bacterial contamination as the cause requires additional testing that should have been done before the material left the supplier’s warehouse.
Endotoxin testing is also a meaningful proxy for manufacturing hygiene. High endotoxin levels in a synthesized peptide indicate problems with reagent quality, water systems, or handling practices — the same conditions that tend to produce other forms of contamination. A clean endotoxin result is evidence that the manufacturing environment met baseline microbiological standards.
The three analytical tests described above are the scientific core of a peptide COA. But a legitimate document also contains a set of administrative and reference elements that allow the researcher to independently verify the data and trace it back to the specific batch of material they received.
Every COA must carry a unique batch or lot number that directly corresponds to the specific synthesis run being reported. This is not a formatting convention — it is the linking identifier that connects the analytical data to a discrete physical quantity of material. Without a lot number, there is no way to confirm that the data on the document relates to the compound in the container.
The date on which the analytical work was performed matters. Peptides are chemically labile compounds — they can oxidize, aggregate, or degrade over time, particularly under improper storage conditions. A COA dated three years before the purchase date provides limited assurance about the current state of the material. Current-year testing, or testing close to the synthesis date with proper cold-chain documentation, is the standard to look for.
The COA must identify the compound by its full chemical name and, where applicable, its Chemical Abstracts Service (CAS) registry number. The CAS number is a unique identifier assigned to every registered chemical substance and provides an unambiguous reference that is independent of common names or trade names. For example, BPC-157 has the CAS number 137525-51-0. If the compound name on the COA does not resolve to the expected CAS number, something is wrong.
The testing laboratory must be identified by name, and its accreditation status should be verifiable. ISO/IEC 17025 accreditation is the international standard for testing and calibration laboratories. An accredited laboratory has demonstrated to an independent accreditation body that its methods, equipment, personnel, and quality management system meet defined competence requirements. Testing performed at an unaccredited facility — or testing claimed to be third-party but performed at a facility under common ownership with the supplier — does not carry the same evidentiary weight.
The following conditions, individually or in combination, are grounds for disqualifying a peptide source before any research material is purchased.
| Element | What It Confirms | Red Flag If Missing |
|---|---|---|
| HPLC chromatogram with area integration table | Quantitative purity of the compound; identifies and measures all impurity peaks | Purity claim is unverifiable; a bare percentage figure without supporting data is meaningless |
| ESI-MS mass spectrum with observed vs. theoretical MW | Confirms molecular identity; verifies correct amino acid sequence and molecular formula | No way to confirm the compound is what the label claims, regardless of HPLC purity result |
| Endotoxin result with USP <85> reference and stated limit | Confirms material is free of bacterial LPS contamination to a defined threshold | Critical research variable uncontrolled; inflammatory assay results become unreliable |
| Unique batch or lot number | Links analytical data to a specific, discrete synthesis run | No traceability; the COA may not correspond to the material you received |
| Test date | Establishes when the analytical work was performed relative to purchase | Data may be stale; no way to assess compound stability over the storage period |
| Compound name and CAS number | Unambiguous chemical identification independent of trade names | Compound identity cannot be cross-referenced against an external registry |
| Third-party laboratory name and accreditation | Independent, accredited analytical work with no commercial bias | Self-reported data; supplier has an incentive to report favourable results |
| HPLC purity ≥98% (≥99% preferred) | Compound meets minimum research-grade purity threshold | Impurity load is high enough to introduce meaningful experimental variability |
In-house testing only. If the COA is produced by the supplier’s internal laboratory rather than an independent third party, it is self-certification. The supplier has a financial incentive to report passing results. Third-party testing severs that conflict of interest.
Missing endotoxin data. Suppliers who omit endotoxin testing are either unaware of its importance (a competence concern) or are aware and have chosen not to test (a transparency concern). Either interpretation is disqualifying for serious research applications.
No lot number on the COA or the product label. If the material cannot be traced to a specific batch, the COA serves no analytical purpose. Some suppliers use a single generic COA for an entire product line, which is not batch-level documentation — it is a template.
Purity below 98%. While different applications may have different tolerance thresholds, 98% is the practical floor for research-grade material. Peptides with purity in the 90–95% range carry significant impurity loads that complicate data interpretation.
No mass confirmation. A COA without ESI-MS data cannot confirm molecular identity. This is the single most important red flag because it means you cannot be certain the compound is what the label states, regardless of what the purity result shows.
Unverifiable laboratory credentials. If the testing laboratory cannot be found via a web search, is not listed on an accreditation body’s registry, or shares an address with the supplier, treat the COA as unverified.
A lot number on a COA is only useful if it can be independently verified. Here is the process for cross-referencing a lot number against supplier records before committing to a purchase.
Step 1: Locate the supplier’s COA database. Legitimate research peptide suppliers maintain a publicly accessible, searchable database of COAs organized by lot number. If the supplier does not have such a database, or if COAs are only available on request rather than published proactively, that is a transparency concern.
Step 2: Search by lot number. Enter the lot number from the product label (or from the COA you have been provided) into the supplier’s database. The result should return a unique COA document corresponding to that specific batch. If no result is returned, or if the lot number returns a COA with a different compound name, the traceability chain is broken.
Step 3: Verify the laboratory identity. The testing laboratory named on the COA should be independently verifiable. Search for the laboratory by name, confirm its address, and check whether it holds ISO/IEC 17025 accreditation through a national accreditation body such as A2LA (American Association for Laboratory Accreditation), UKAS (United Kingdom Accreditation Service), or an equivalent organization in the relevant jurisdiction.
Step 4: Check the test date against the purchase date. The COA test date should be reasonably recent. For long-lived stable peptides stored under appropriate conditions, COA data from within the past 12–24 months is generally acceptable. For more labile compounds or older stock, request confirmation of re-testing or storage condition documentation.
Step 5: Match the compound name and CAS number. Confirm that the compound name on the COA matches the product label exactly and that the CAS number corresponds to the correct compound via a reference database such as PubChem or the CAS registry. This step takes less than two minutes and eliminates any ambiguity about what is in the container.
Biohacker’s approach to peptide COA purity testing is built around three principles: every batch is tested independently, all three analytical methods are applied as a minimum standard, and every COA is published and searchable before the corresponding material is made available for research.
Every Biohacker peptide — including BPC-157 and the full catalogue — undergoes HPLC purity analysis, ESI-MS mass confirmation, and endotoxin testing to USP <85> as a baseline requirement. There is no minimum order threshold for accessing COA data, and there is no request-only system — all COAs are published proactively on the Biohacker COA page and indexed by lot number.
The average HPLC purity across all Biohacker batches is 99.67%. This figure is a direct output of testing — not a specification target — and reflects the actual distribution of purity results across independent synthesis runs verified by third-party laboratories. Batches that do not meet the 99% threshold are not released for research use.
The rationale for capsule delivery format is partly a purity preservation argument. Lyophilized peptide sealed in a pharmaceutical-grade capsule within a sealed container is less susceptible to the atmospheric oxygen and moisture exposure that degrades purity over time in reconstituted solutions. Researchers using Biohacker capsules benefit from the same batch-level COA documentation as any other format, with the added assurance that the physical format is compatible with longer-term storage without reconstitution-related degradation. Learn more about our testing standards on the about page and find answers to common questions in the FAQ.
No single analytical method is sufficient for research-grade peptide verification. HPLC confirms the percentage of the target compound relative to all detected species, but cannot confirm molecular identity. ESI-MS mass spectrometry confirms identity but cannot detect all impurity classes. Endotoxin testing addresses a contamination risk that neither chromatographic nor spectrometric methods are designed to catch. The three-method requirement exists because each test covers a blind spot in the others. A peptide COA that omits any one of the three is incomplete for research purposes.
HPLC (High-Performance Liquid Chromatography) purity is the percentage of the total UV-absorbing material in a peptide sample that is identified as the target compound. It is measured by injecting the dissolved sample into a chromatography column, separating the components by their chemical properties, and calculating the area of the target compound’s peak as a proportion of all peaks in the chromatogram. A result of ≥99% means that at least 99% of the detectable material is the compound of interest, with all remaining impurities — synthesis by-products, deletion sequences, oxidised residues — accounting for 1% or less. This threshold is the accepted standard for research-grade peptides.
Endotoxins are lipopolysaccharide fragments from gram-negative bacterial membranes that are potent activators of immune and inflammatory pathways. Even at concentrations below 1.0 EU/mL, endotoxins can trigger measurable biological responses in cell-based assays, confounding any experiment that involves cytokine measurement, NF-κB signalling, macrophage behaviour, or related readouts. Because peptide synthesis is performed in aqueous environments using biological buffers and reagents that may harbour gram-negative bacterial contamination, endotoxin testing to USP <85> is a mandatory quality step for research-grade material. A supplier that omits this test is leaving an uncontrolled variable in your experimental system.
A batch number (also called a lot number) is a unique alphanumeric identifier assigned to a specific, discrete synthesis run of a compound. On a COA, the batch number is the linking identifier between the analytical data reported on the document and the physical material in a container. Without a batch number, a COA is a generic document — it may accurately represent some prior synthesis run but cannot be confirmed to represent the material you actually received. Batch-level COAs are the standard for pharmaceutical and research-grade materials because they provide traceability: if a question arises about a specific container of material, the batch number allows you to pull the corresponding analytical data and verify its source.
HPLC measures purity — the relative abundance of compound species in the sample — but it does not confirm molecular identity. A sample could theoretically show high HPLC purity while still containing the wrong compound, if that compound has similar chromatographic behaviour to the target peptide. ESI-MS (Electrospray Ionization Mass Spectrometry) is the complementary technique that confirms molecular identity by measuring the actual mass of the compound and comparing it to the theoretical mass calculated from the amino acid sequence. Only when both tests are performed together — HPLC confirming purity and ESI-MS confirming identity — can you be confident that the sample is both what it claims to be and free of significant impurities.
ISO/IEC 17025 is the international standard for testing and calibration laboratories. A laboratory that holds this accreditation has been assessed by an independent national accreditation body and found to meet defined requirements for technical competence, equipment calibration, method validation, staff qualifications, and quality management systems. For peptide COA purposes, ISO/IEC 17025 accreditation means that the analytical results were generated under conditions that have been externally verified for reliability and accuracy. Testing performed at an unaccredited laboratory may use comparable methods, but without independent oversight, the reliability of the results cannot be independently confirmed.
The generally accepted minimum for research-grade peptides is ≥98% HPLC purity, with ≥99% being the preferred standard for applications requiring high experimental reproducibility. Peptides below 98% carry an impurity load that is large enough to introduce meaningful variability into sensitive biological assays. For researchers working with cell-based models, receptor binding studies, or any application where compound dose-response relationships matter, the 2% impurity allowance at the 98% threshold can represent a non-trivial contribution to experimental noise. Biohacker’s catalogue targets ≥99% purity with a fleet-wide average of 99.67%, verified by independent third-party HPLC analysis on every batch.
The most reliable verification steps are: (1) locate the COA in the supplier’s publicly accessible, lot-number-indexed database rather than accepting a PDF provided directly by the supplier; (2) identify the testing laboratory by name and confirm its existence and accreditation status through a national accreditation body’s registry; (3) check that the lot number on the COA matches the lot number on the product label exactly; (4) confirm that the compound name and CAS number on the COA match the product specification. A fabricated COA typically either invents a laboratory name, uses a real laboratory name without having contracted that laboratory, or applies a single COA document to multiple batches. Lot-number cross-referencing in a publicly searchable database is the most effective single step against fabrication.
Research Disclaimer: All content on this page is provided for educational and informational purposes relating to laboratory research. Biohacker peptide products are sold exclusively for in vitro and ex vivo research use by qualified professionals. They are not approved by the FDA or any equivalent regulatory authority for human or veterinary use, are not drugs or medicines, and are not intended for administration to humans or animals. Nothing in this article constitutes medical advice, clinical guidance, or a recommendation to use any compound for any purpose other than scientific research conducted under appropriate institutional oversight.
For a practical example of why purity matters in active research, see our BPC-157 research overview — a compound where impurity fractions could confound GI and musculoskeletal endpoints. For delivery-method context, see Oral vs Injectable Peptides.
Biohacker’s research compounds are independently authenticated by accredited third-party laboratories — every batch is tested by specialists in analytical chemistry before it ships. Our team’s compound sourcing standards require a minimum 99% HPLC purity floor, ESI-MS mass confirmation, and endotoxin compliance to USP <85> on every lot. Average purity across the catalogue is 99.67%. These are not supplier-claimed figures — they are independently verified results, published batch-by-batch at biohacker.dev-up.click/coas/.
All Biohacker compounds are for laboratory and scientific research use only. They are not intended for human or veterinary use, clinical application, or diagnostic purposes.